[go: up one dir, main page]

WO2014087307A3 - Compositions and methods for the treatment of metabolic syndrome and diabetes - Google Patents

Compositions and methods for the treatment of metabolic syndrome and diabetes Download PDF

Info

Publication number
WO2014087307A3
WO2014087307A3 PCT/IB2013/060502 IB2013060502W WO2014087307A3 WO 2014087307 A3 WO2014087307 A3 WO 2014087307A3 IB 2013060502 W IB2013060502 W IB 2013060502W WO 2014087307 A3 WO2014087307 A3 WO 2014087307A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compositions
diabetes
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/060502
Other languages
French (fr)
Other versions
WO2014087307A2 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014087307A2 publication Critical patent/WO2014087307A2/en
Publication of WO2014087307A3 publication Critical patent/WO2014087307A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing metabolic syndrome and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
PCT/IB2013/060502 2012-12-04 2013-11-29 Compositions and methods for the treatment of metabolic syndrome and diabetes Ceased WO2014087307A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5060CH2012 2012-12-04
IN5060/CHE/2012 2012-12-04

Publications (2)

Publication Number Publication Date
WO2014087307A2 WO2014087307A2 (en) 2014-06-12
WO2014087307A3 true WO2014087307A3 (en) 2014-07-31

Family

ID=50884094

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/060502 Ceased WO2014087307A2 (en) 2012-12-04 2013-11-29 Compositions and methods for the treatment of metabolic syndrome and diabetes

Country Status (1)

Country Link
WO (1) WO2014087307A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014106804A2 (en) * 2013-01-04 2014-07-10 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome and diabetes
IL261756B2 (en) 2016-03-17 2023-11-01 Thiogenesis Therapeutics Inc Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
WO2018152428A1 (en) * 2017-02-17 2018-08-23 Illustris Pharmaceuticals, Inc. Compounds, compositions and use thereof
CN118924717A (en) 2017-09-20 2024-11-12 硫创治疗公司 Methods for treating cysteamine-sensitive disorders
CN113272278A (en) * 2018-11-16 2021-08-17 因西利亚治疗私人有限公司 Substituted pyridine carboxylic acids, process for their preparation and compositions containing them
CN115433144B (en) * 2022-10-09 2023-09-19 燃点(南京)生物医药科技有限公司 A kind of fatty acid ester compound and its preparation method and application

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131995A1 (en) * 1983-07-19 1985-01-23 Maggioni-Winthrop S.P.A. Compounds with hypolipemic activity
US5120738A (en) * 1989-10-06 1992-06-09 Fujirebio Inc. Pantothenic acid derivatives
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
US20120184585A1 (en) * 2009-09-01 2012-07-19 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2012149352A1 (en) * 2011-04-29 2012-11-01 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses
WO2014068463A2 (en) * 2012-11-03 2014-05-08 Mahesh Kandula Compositions and methods for the treatment of inflammation and metabolic disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131995A1 (en) * 1983-07-19 1985-01-23 Maggioni-Winthrop S.P.A. Compounds with hypolipemic activity
US5120738A (en) * 1989-10-06 1992-06-09 Fujirebio Inc. Pantothenic acid derivatives
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
US20120184585A1 (en) * 2009-09-01 2012-07-19 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2012149352A1 (en) * 2011-04-29 2012-11-01 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses
WO2014068463A2 (en) * 2012-11-03 2014-05-08 Mahesh Kandula Compositions and methods for the treatment of inflammation and metabolic disorders

Also Published As

Publication number Publication date
WO2014087307A2 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
MX365108B (en) Piperidine derivatives for gpr119 agonist.
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2014174425A3 (en) Compositions and methods for the treatment of orthostasis and neurological diseases
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014080307A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014195810A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
WO2013167998A3 (en) Compositions and methods for the treatment of autonomic and other neurological disorders
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
WO2014083476A3 (en) Compositions and methods for the treatment of metabolic and lipid disorders
WO2015015403A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014091465A3 (en) Compositions and methods for the treatment of metabolic syndrome and lipid disorders
MX386208B (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS.
WO2014068461A3 (en) Compositions and methods for the treatment of acute inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13860578

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13860578

Country of ref document: EP

Kind code of ref document: A2